Skip to content
The Policy VaultThe Policy Vault

bremelanotide — Blue Cross Blue Shield of New Mexico

acquired, generalized hypoactive sexual desire disorder (HSDD)

Initial criteria

  • ONE of the following: A. ALL of the following: 1. The patient's benefit plan covers the requested agent AND 2. The patient is premenopausal AND 3. BOTH of the following: A. ONE of the following: 1. The patient has a diagnosis of acquired, generalized hypoactive sexual desire disorder (HSDD) OR 2. The patient has had a diagnosis of female sexual interest/arousal disorder (FSIAD) AND B. BOTH of the following: 1. The patient’s HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty AND 2. The patient’s symptoms of low sexual desire have been present for at least 6 months AND 4. The HSDD is NOT due to ANY of the following: A. A co-existing medical or psychiatric condition OR B. Problems within the relationship OR C. The effects of a medication or other drug substance OR B. BOTH of the following: 1. The patient's benefit plan covers the requested agent AND 2. The patient has another FDA labeled or compendia supported indication for the requested agent and route of administration
  • The patient has tried and had an inadequate response to other treatment modalities (e.g., education, modification factors thought to be contributing to HSDD/FSIAD, and sex therapy)
  • The patient will NOT be using the requested agent in combination with another target agent in this program for the requested indication
  • The patient does NOT have any FDA labeled contraindications to the requested agent

Reauthorization criteria

  • The patient has been previously approved for the requested agent through the plan’s prior authorization process
  • The patient’s benefit plan covers the requested agent
  • The patient is premenopausal
  • The patient has had clinical benefit with the requested agent
  • The patient will NOT be using the requested agent in combination with another target agent in this program for the requested indication
  • The patient does NOT have any FDA labeled contraindications to the requested agent

Approval duration

initial: 3 months (BCBSNM); renewal: 12 months